BTK and B-cell chronic lymphocytic leukemia: Although the constitutive VLA-4 activation and cell adhesion were reduced, BCR-mediated VLA-4 activation is retained in ibrutinib-treated CLL cells, demonstrating that the inhibition of BTK activity is not sufficient to block BCR-dependent VLA-4 activation.